Novartis has claimed accelerated approval from the FDA for Vanrafia, one of a trio of therapies it hopes will revolutionise the treatment of rare kidney disease IgA nephropathy (IgAN). Vanrafia ...

The acquisition would significantly boost Novartis’ position in rare kidney disease IgA nephropathy (IgAN), which the Swiss big pharma is targeting with oral complement factor B inhibitor ...

Before setting your 2025 Fantasy football draft strategy, be sure to check out the 2025 Fantasy football rankings and cheat sheets from the proven computer model at SportsLine. Last year ...

Disclaimer: This Working Paper should not be reported as representing the views of the IMF.The views expressed in this Working Paper are those of the author(s) and do not necessarily represent those ...